Ravuconazole (codenamed BMS-207147 and ER-30346) is a potent triazole antifungal, the development of which was discontinued in 2007.[1] The drug has shown to have a similar spectrum of activity to voriconazole, with an increased half-life.[2] However, ravuconazole has limited activity against species of Fusarium, Scedosporium, and Zygomycetes.[3][4]

See also

References

  1. ^ "Ravuconazole". AdisInsight. Springer Nature Switzerland AG. Retrieved 12 November 2017.
  2. ^ Pasqualotto AC, Denning DW. "Ravuconazole". The Aspergillus Website. Retrieved 18 February 2010.
  3. ^ Pasqualotto AC, Thiele KO, Goldani LZ (February 2010). "Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole". Current Opinion in Investigational Drugs. 11 (2): 165–174. PMID 20112166.
  4. ^ Pfaller MA, Messer SA, Hollis RJ, Jones RN (April 2002). "Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000". Antimicrobial Agents and Chemotherapy. 46 (4): 1032–1037. doi:10.1128/AAC.46.4.1032-1037.2002. PMC 127116. PMID 11897586.

External links